Another study from the French Lung Cancer Group (GFPC) revealed that 6/23 patients with HER2-mutant relapsed NSCLC responded to ICIs (ORR = 27.3%), with a median PFS OS and DoR of 2.2, 20.4, and 15.2 months, respectively. This evidence concerns the gene ERBB2 and lung carcinoma.